2020
DOI: 10.1186/s12935-020-01374-w
|View full text |Cite
|
Sign up to set email alerts
|

A methylation‐based mRNA signature predicts survival in patients with gastric cancer

Abstract: Background: Evidence suggests that altered DNA methylation plays a causative role in the occurrence, progression and prognosis of gastric cancer (GC). Thus, methylated-differentially expressed genes (MDEGs) could potentially serve as biomarkers and therapeutic targets in GC. Methods: Four genomics profiling datasets were used to identify MDEGs. Gene Ontology enrichment and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment analysis were used to explore the biological roles of MDEGs in GC. Univariate C… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
10
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(10 citation statements)
references
References 48 publications
(47 reference statements)
0
10
0
Order By: Relevance
“…Table 8 provides information about 44 diseases and the corresponding survival prediction algorithms utilized in these diseases. A deeper analysis of Table 8 shows that Cox-PH and lasso Cox-PH models have been extensively utilized for disease specific survival prediction i.e., ASCVD 29,111 , bladder cancer 40,82 , colorectal cancer 7477 , hepatocellular carcinoma 43,86,87 , ovarian cancer 88–90,103 , lung adenocarcinoma 101 , heart failure 118 , HER2-negative metastatic breast cancer 67 , pancreatic cancer 26,71 , trauma 120 , nasopharyngeal carcinoma 66 , triple-negative breast cancer 68 , lymphoma 85 , breast cancer 40,81,82 , ovarian cancer 88–90,103 , and lower-grade glioma 80 , cardiovascular disease 112,114117 , invasive ductal carcinoma 70 , liver transplantation 119 , gastric cancer 42 , lung cancer 27 , esophageal squamous cell carcinoma 79 , glioma 69 , and liver cancer 41 . RSF has been employed in 13 studies for 6 diseases namely, ASCVD 29 , bladder cancer 82 , gastrointestinal cancer 30 , cervical cancer 73 , liver transplantation 119 , and heart failure 118 .…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…Table 8 provides information about 44 diseases and the corresponding survival prediction algorithms utilized in these diseases. A deeper analysis of Table 8 shows that Cox-PH and lasso Cox-PH models have been extensively utilized for disease specific survival prediction i.e., ASCVD 29,111 , bladder cancer 40,82 , colorectal cancer 7477 , hepatocellular carcinoma 43,86,87 , ovarian cancer 88–90,103 , lung adenocarcinoma 101 , heart failure 118 , HER2-negative metastatic breast cancer 67 , pancreatic cancer 26,71 , trauma 120 , nasopharyngeal carcinoma 66 , triple-negative breast cancer 68 , lymphoma 85 , breast cancer 40,81,82 , ovarian cancer 88–90,103 , and lower-grade glioma 80 , cardiovascular disease 112,114117 , invasive ductal carcinoma 70 , liver transplantation 119 , gastric cancer 42 , lung cancer 27 , esophageal squamous cell carcinoma 79 , glioma 69 , and liver cancer 41 . RSF has been employed in 13 studies for 6 diseases namely, ASCVD 29 , bladder cancer 82 , gastrointestinal cancer 30 , cervical cancer 73 , liver transplantation 119 , and heart failure 118 .…”
Section: Resultsmentioning
confidence: 99%
“…Figure 3 provides an overview of multiple survival prediction studies that encompass a range of cancer subtypes, either within a pancancer context or within the context of predicting survival for different subtypes. A total of 14 studies have taken into account multiple cancer subtypes whereas the majority of the studies have only covered only a single type of cancer subtype such as colorectal cancer 109 , lymphoma 85 , colon adenocarcinoma 39 , gastric cancer 42 and so on.…”
Section: Rq I Ii Iii: Survival Predictors Distribution Analysis Acros...mentioning
confidence: 99%
See 2 more Smart Citations
“…Of note, CHRNB2 expression was significantly suppressed only in the TP53 mutation group of GC patients [ 25 ]. Also, a study identifying methylated-differentially expressed genes (MDEGs) on a genome-wide scale systematically explored Multi-Omics cohorts from the TGCA and GEO to construct a new MDEGs-based signature [ 26 ]. The eight-MDEGs signature (TREM2, MICAL2, INHBA, PCSK5, NRP1, YAP1, RAI14, and MATN3) was identified and validated the prognosis performance.…”
Section: Epigenomics-based Validation Of Predictive and Prognostic Ma...mentioning
confidence: 99%